Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 2.57000
forwardPE 32.19960
debtToEquity 6.67500
earningsGrowth 0.02400
revenueGrowth 0.08900
grossMargins 0.78192
operatingMargins 0.23256
trailingEps 43.53000
forwardEps 32.68000

SUNPHARMA's current ratio of 2.57 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects SUNPHARMA's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
With positive gross and operating margins, SUNPHARMA demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
SUNPHARMA's forward EPS being less than trailing EPS suggests the company may see a drop in profitability this year. This signals potential financial challenges and a less optimistic outlook for earnings growth.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

SUNPHARMA's price has often been near the lower end of the projected range. This ongoing trend suggests that investor confidence might be waning, and the stock could face challenges in gaining upward momentum.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


The recent buy bias for Sun Pharmaceutical Industries Limited from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see Sun Pharmaceutical Industries Limited as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.